Home LiteratureArticle Details
PMID: 15241593 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Interleukin-6 and insulin sensitivity: friend or foe?

Diabetologia ·Vol. 47 ·No. 7 ·2004-07-00 ·Pages 1135-1142

Carey AL, Febbraio MA

Abstract

暂无摘要

MeSH Terms
Animals Biological Transport Cytokines/physiology Glucose/metabolism Humans Insulin/physiology Insulin Resistance Interleukin-6/blood,physiology Signal Transduction
Chemicals
Cytokines Insulin Interleukin-6 Glucose
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Carey A L
The Skeletal Muscle Research Laboratory, School of Medical Sciences, RMIT University, PO Box 71, Bundoora 3083, Victoria, Australia.
Febbraio M A
The Skeletal Muscle Research Laboratory, School of Medical Sciences, RMIT University, PO Box 71, Bundoora 3083, Victoria, Australia. [email protected].
References (92)
92 references, click to expand
  1. Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes.
    Hepatology. 1998 May;27(5):1296-303 PMID: 9581683
  2. The effects of infection of thermal injury by Pseudomonas aeruginosa PAO1 on the murine cytokine response.
    Cytokine. 2001 Nov 21;16(4):160-8 PMID: 11792126
  3. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.
    Science. 1993 Jan 1;259(5091):87-91 PMID: 7678183
  4. Interleukin-6 gene polymorphism and insulin sensitivity.
    Diabetes. 2000 Mar;49(3):517-20 PMID: 10868978
  5. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3.
    FASEB J. 2001 Mar;15(3):562-4 PMID: 11259367
  6. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes.
    Life Sci. 2000 Jun 8;67(3):291-300 PMID: 10983873
  7. MAP kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor substrate-1 on serine residues 307, 612 and 632.
    Diabetologia. 2003 Nov;46(11):1532-42 PMID: 14579029
  8. Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans.
    J Physiol. 2003 Apr 15;548(Pt 2):631-8 PMID: 12640021
  9. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells.
    J Biol Chem. 2001 Oct 12;276(41):38052-60 PMID: 11498541
  10. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice.
    Diabetes. 2003 Nov;52(11):2784-9 PMID: 14578297
  11. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.
    Nature. 1986 Nov 6-12;324(6092):73-6 PMID: 3491322
  12. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue.
    J Physiol. 2002 Aug 15;543(Pt 1):379-86 PMID: 12181308
  13. Skeletal muscle interleukin-6 and tumor necrosis factor-alpha release in healthy subjects and patients with type 2 diabetes at rest and during exercise.
    Metabolism. 2003 Jul;52(7):939-44 PMID: 12870175
  14. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.
    J Clin Endocrinol Metab. 2000 Sep;85(9):3338-42 PMID: 10999830
  15. Effect of proinflammatory interleukins on jejunal nutrient transport.
    Gut. 2000 Aug;47(2):184-91 PMID: 10896908
  16. Effect of prolonged, submaximal exercise and carbohydrate ingestion on monocyte intracellular cytokine production in humans.
    J Physiol. 2000 Nov 1;528(Pt 3):647-55 PMID: 11060137
  17. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus.
    J Clin Invest. 1985 Jul;76(1):149-55 PMID: 3894418
  18. Cytokine regulation of facilitated glucose transport in human articular chondrocytes.
    J Immunol. 2001 Dec 15;167(12):7001-8 PMID: 11739520
  19. Interleukin-6 induces cellular insulin resistance in hepatocytes.
    Diabetes. 2002 Dec;51(12):3391-9 PMID: 12453891
  20. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.
    Biochem J. 1998 Sep 1;334 ( Pt 2):297-314 PMID: 9716487
  21. Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content.
    J Physiol. 2001 Dec 1;537(Pt 2):633-9 PMID: 11731593
  22. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.
    J Clin Endocrinol Metab. 1997 Dec;82(12):4196-200 PMID: 9398739
  23. Inhibition by recombinant human interleukin-6 of the glucagon-dependent induction of phosphoenolpyruvate carboxykinase and of the insulin-dependent induction of glucokinase gene expression in cultured rat hepatocytes: regulation of gene transcription and messenger RNA degradation.
    Hepatology. 1994 Dec;20(6):1577-83 PMID: 7527006
  24. Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes.
    Biochem Biophys Res Commun. 1996 Mar 18;220(2):241-5 PMID: 8645290
  25. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion.
    Obes Res. 2001 Jul;9(7):414-7 PMID: 11445664
  26. Endocrine and carbohydrate responses to interleukin-6 in vivo.
    Circ Shock. 1994 Dec;44(4):210-5 PMID: 7628063
  27. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction.
    Diabetes. 2004 Jul;53(7):1643-8 PMID: 15220185
  28. Interleukin-6 stimulates hepatic triglyceride secretion in rats.
    Endocrinology. 1995 May;136(5):2143-9 PMID: 7720663
  29. Interleukin-6 production by contracting human skeletal muscle: autocrine regulation by IL-6.
    Biochem Biophys Res Commun. 2003 Oct 17;310(2):550-4 PMID: 14521945
  30. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects.
    J Biol Chem. 2003 Nov 14;278(46):45777-84 PMID: 12952969
  31. A family of cytokine-inducible inhibitors of signalling.
    Nature. 1997 Jun 26;387(6636):917-21 PMID: 9202125
  32. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes.
    J Biol Chem. 2003 Apr 18;278(16):13740-6 PMID: 12560330
  33. Impairment of insulin signaling in human skeletal muscle cells by co-culture with human adipocytes.
    Diabetes. 2002 Aug;51(8):2369-76 PMID: 12145147
  34. Interleukin-6 gene expression is increased in insulin-resistant rat skeletal muscle following insulin stimulation.
    Biochem Biophys Res Commun. 2003 Mar 21;302(4):837-40 PMID: 12646246
  35. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone.
    Biochem Biophys Res Commun. 2003 Nov 14;311(2):372-9 PMID: 14592424
  36. Increased secretion of tumour necrosis factor and interleukin 6 from isolated, perfused liver of rats after partial hepatectomy.
    Cytokine. 2001 Jan 7;13(1):60-64 PMID: 11145844
  37. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production.
    Proc Natl Acad Sci U S A. 1987 Jan;84(1):228-31 PMID: 3491991
  38. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans.
    FASEB J. 2003 May;17(8):884-6 PMID: 12626436
  39. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness.
    Diabetologia. 2004 Jun;47(6):1029-37 PMID: 15168015
  40. Relationship of TNF to interleukins.
    Immunol Ser. 1992;56:499-566 PMID: 1550874
  41. Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise.
    FASEB J. 2003 Nov;17(14):2166-8 PMID: 12958150
  42. Cytokines and type 2 diabetes mellitus.
    JAMA. 2001 Nov 14;286(18):2233 PMID: 11710884
  43. The soluble interleukin-6 receptor is generated by shedding.
    Eur J Immunol. 1993 Feb;23(2):473-80 PMID: 8436181
  44. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha.
    J Clin Invest. 1994 Oct;94(4):1543-9 PMID: 7523453
  45. Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha, growth hormone, and IL-6 in 3T3-L1 adipocytes.
    Horm Metab Res. 2003 Mar;35(3):147-52 PMID: 12734774
  46. Role of cytokines in inducing hyperlipidemia.
    Diabetes. 1992 Oct;41 Suppl 2:97-101 PMID: 1526345
  47. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians.
    Hum Genet. 2003 Apr;112(4):409-13 PMID: 12589429
  48. Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-alpha levels after prolonged running.
    Am J Physiol Cell Physiol. 2001 Apr;280(4):C769-74 PMID: 11245592
  49. Gene expression of receptors for IL-6, LIF, and CNTF in regenerating skeletal muscles.
    J Histochem Cytochem. 2000 Sep;48(9):1203-13 PMID: 10950877
  50. Mechanisms of TNF-alpha-induced insulin resistance.
    Exp Clin Endocrinol Diabetes. 1999;107(2):119-25 PMID: 10320052
  51. Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment.
    J Clin Invest. 1991 Sep;88(3):811-6 PMID: 1653277
  52. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site.
    J Immunol. 1994 May 15;152(10):4958-68 PMID: 8176214
  53. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.
    Am J Physiol Endocrinol Metab. 2001 May;280(5):E745-51 PMID: 11287357
  54. Intracerebroventricular interleukin-6 treatment decreases body fat in rats.
    Biochem Biophys Res Commun. 2002 Apr 26;293(1):560-5 PMID: 12054638
  55. Comparison of the effects of insulin, PDGF, interleukin-6, and interferon-gamma on glucose transport in 3T3-L1 cells: lack of cross-talk between tyrosine kinase receptors and JAK/STAT pathways.
    Diabetologia. 1996 Dec;39(12):1432-9 PMID: 8960823
  56. High interleukin-6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production.
    Clin Exp Immunol. 1989 Aug;77(2):221-5 PMID: 2505958
  57. Scavenging nitric oxide reduces hepatocellular injury after endotoxin challenge.
    Am J Physiol Gastrointest Liver Physiol. 2001 Jul;281(1):G173-81 PMID: 11408270
  58. Evidence for IL-6 production by and effects on the pancreatic beta-cell.
    J Immunol. 1989 Aug 15;143(4):1188-91 PMID: 2501390
  59. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro.
    J Clin Endocrinol Metab. 2002 May;87(5):2084-9 PMID: 11994345
  60. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus.
    Acta Diabetol. 1999 Jun;36(1-2):67-72 PMID: 10436255
  61. Interleukins.
    Annu Rev Med. 1986;37:173-8 PMID: 3518604
  62. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies.
    Proc Natl Acad Sci U S A. 1980 Dec;77(12):7152-6 PMID: 6164058
  63. Endocrinologic and metabolic effects of interleukin-6 in humans.
    Am J Physiol. 1995 May;268(5 Pt 1):E813-9 PMID: 7762632
  64. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study.
    Diabetes. 2003 Jul;52(7):1872-6 PMID: 12829659
  65. Circulating interleukin 6 concentrations and insulin resistance in patients with cancer.
    Br J Surg. 1998 Dec;85(12):1658-62 PMID: 9876070
  66. Cytokines and endotoxin induce cytokine receptors in skeletal muscle.
    Am J Physiol Endocrinol Metab. 2000 Jul;279(1):E196-205 PMID: 10893340
  67. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.
    Diabetologia. 1997 Nov;40(11):1286-92 PMID: 9389420
  68. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity.
    FASEB J. 2004 Jun;18(9):992-4 PMID: 15059966
  69. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin.
    Mol Cell Biol. 2001 Aug;21(15):5050-62 PMID: 11438661
  70. Hepatosplanchnic clearance of interleukin-6 in humans during exercise.
    Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E397-402 PMID: 12857677
  71. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells.
    J Immunol. 1989 Jan 1;142(1):144-7 PMID: 2783321
  72. Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by tumour necrosis factor-alpha.
    J Mol Endocrinol. 1992 Aug;9(1):61-72 PMID: 1515026
  73. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130.
    Cell. 1989 Aug 11;58(3):573-81 PMID: 2788034
  74. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.
    JAMA. 2001 Jul 18;286(3):327-34 PMID: 11466099
  75. Biological and clinical aspects of interleukin 6.
    Immunol Today. 1990 Dec;11(12):443-9 PMID: 2127356
  76. Interleukin-6 stimulates lipolysis and fat oxidation in humans.
    J Clin Endocrinol Metab. 2003 Jul;88(7):3005-10 PMID: 12843134
  77. Molecular basis of the cell specificity of cytokine action.
    Biochim Biophys Acta. 2002 Nov 11;1592(3):281-96 PMID: 12421672
  78. Effects of cytokines on the liver.
    Hepatology. 1991 Feb;13(2):364-75 PMID: 1995444
  79. Interleukin-6-deficient mice develop mature-onset obesity.
    Nat Med. 2002 Jan;8(1):75-9 PMID: 11786910
  80. The phosphotidyl inositol 3-kinase/Akt signal pathway is involved in interleukin-6-mediated Mcl-1 upregulation and anti-apoptosis activity in basal cell carcinoma cells.
    J Invest Dermatol. 2002 Nov;119(5):1121-7 PMID: 12445202
  81. Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
    J Clin Invest. 1992 May;89(5):1681-4 PMID: 1569207
  82. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes.
    Biochem Biophys Res Commun. 2003 Feb 21;301(4):1045-50 PMID: 12589818
  83. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex.
    Biochim Biophys Acta. 2002 Nov 11;1592(3):251-63 PMID: 12421670
  84. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways.
    J Biol Chem. 1999 Aug 13;274(33):23013-9 PMID: 10438468
  85. Autocrine up-regulation of glucocorticoid receptors by interleukin-6 in human osteoblast-like cells.
    Calcif Tissue Int. 2001 Nov;69(5):293-8 PMID: 11768200
  86. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation.
    J Clin Endocrinol Metab. 1997 Dec;82(12):4167-70 PMID: 9398733
  87. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway.
    Oncogene. 2001 Sep 13;20(41):5799-809 PMID: 11593385
  88. Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6.
    Proc Natl Acad Sci U S A. 1987 May;84(9):2590-4 PMID: 3472226
  89. Trophic effect of ciliary neurotrophic factor on denervated skeletal muscle.
    Cell. 1994 Feb 11;76(3):493-504 PMID: 8313470
  90. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6.
    J Physiol. 2000 Nov 15;529 Pt 1:237-42 PMID: 11080265
  91. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles.
    FASEB J. 2002 Sep;16(11):1335-47 PMID: 12205025
  92. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene.
    EMBO J. 1987 Oct;6(10):2939-45 PMID: 3500852
Article Info
Journal
Diabetologia
Abbr.
Diabetologia
ISSN
0012-186X
DOI
10.1007/s00125-004-1447-y
Email
[email protected]
Published
2004-07-00
Epub
2004-00-07
Pages
1135-1142
Language
English
Region
Germany
NLM ID
0006777
Subset
IM
External Links
PubMed source DOI: 10.1007/s00125-004-1447-y View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2